Research Article
Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients
Table 3
Hepatic toxicity in both groups.
| | Grade | HCV positive (group A; = 7) | HCV negative (group B; = 21) | value |
| ALT | G 0 | 1 (14.3%) | 9 (42.8%) | 0.15 | G 1 | 4 (57.1%) | 11 (52.4%) | G 2 | 2 (28.6%) | 1 (4.8%) |
| AST | G 0 | 1 (14.3%) | 12 (57.1%) | 0.07 | G 1 | 4 (57.1%) | 8 (38.1%) | G 2 | 2 (28.6%) | 1 (4.8%) |
| Bilirubin | G 0 | 5 (71.4%) | 21 (100%) | 0.06 | G 1 | 1 (14.3%) | 0 (0%) | G 2 | 1 (14.3%) | 0 (0%) |
| INR | G 0 | 4 (57.1%) | 20 (95.2%) | 0.04* | G 1 | 3 (42.9%) | 1 (4.8%) |
| Albumin | G 0 | 6 (85.7%) | 21 (100%) | 0.25 | G 1 | 0 (0%) | 0 (0%) | G 2 | 1 (14.3%) | 0 (0%) |
| Alkaline phosphatase | G 0 | 3 (42.9%) | 14 (66.7%) | 0.21 | G 1 | 3 (42.9%) | 7 (33.3%) | G 2 | 1 (14.3%) | 0 (0%) |
| Hepatic failure# | G 0 | 6 (85.7%) | | 0.25 | G 3 | 0 (0%) | | G 4 | 1 (14.3%) | |
|
|
means significant ( < 0.05).
#means hepatic encephalopathy.
|